p53 is one of your cells' main quality-control bosses. When DNA gets damaged, p53 can slam the brakes on cell division, call in repair crews, or order the cell to self-destruct if things look beyond repair. That is why people call it the "guardian of the genome." Very dramatic, very deserved. When TP53 is mutated, that security chief either goes missing or starts showing up to work in flip-flops and ignoring the alarms. In acute myeloid leukemia, or AML, TP53 mutations are bad news and usually travel with rough outcomes and stubborn resistance to treatment [2,3].
The Y220C mutation is a bit of a special weirdo. It is not the most common TP53 mutation in AML, but it is interesting because it creates a physical cavity in p53 that drug designers can target. That turns a scary mutation into something almost comically tangible: less "fate of the cell" and more "have we tried tightening the loose screw?" [1,4]
Rezatapopt: the molecular tailor
In the new Blood study, Carter and colleagues tested rezatapopt, also called PC14586, a drug designed to fit into that Y220C-created pocket and stabilize p53 in a wild-type-like shape. And, to be fair, it worked - at least for the first part of the job. The drug refolded mutant p53 into a more normal conformation and switched on p53 target genes, basically reminding the protein how to read its old script [1].
If this were a crime show, that would be the moment the detective pins photos to the wall and says, "We got him." But then the episode would have 23 minutes left, which means we absolutely did not get him.
Because in AML cells, restored p53 did not trigger much cell death on its own. That is the paper's big plot twist. The protein looked more normal. It talked more like normal p53. But the leukemia cells still refused to collapse in a satisfyingly cinematic fashion. Cancer, as usual, declined to cooperate with the first draft.
Why the fix wasn't enough
The researchers found at least two reasons rezatapopt alone was underpowered in AML. First, p53 reactivation also boosted MDM2, a protein that acts like p53's annoying hall monitor and helps shut it down. Second, XPO1, a nuclear export protein, also limited p53's activity. So even after p53 got its makeover, AML cells kept finding ways to shove it out of the spotlight [1].
Then came the extra wrinkle. Normal wild-type p53 can physically interact with pro-survival proteins like BCL-2, BCL-xL, and MCL-1, helping push damaged cells toward apoptosis. The refolded p53 in this study did not seem to do that properly. In other words, the actor remembered the lines but still missed some of the fight choreography.
That matters because AML, especially TP53-mutant AML, is notorious for being hard to kill. Reviews from the past few years keep landing on the same depressing group chat summary: standard therapies often underperform, remissions do not last long, and better targeted strategies are badly needed [2-4].
The combo episode looks better
Here is the part that makes this paper worth leaning toward the bar and saying, "Okay, now we're talking."
When the team paired rezatapopt with inhibitors of MDM2, XPO1, or BCL-2, they saw much stronger leukemia cell death and better survival in mouse models [1]. Translation: fixing the broken p53 shape may be necessary, but AML still needs a second shove. This is less a solo superhero movie and more an Avengers situation. Rezatapopt gets p53 back in costume, then partner drugs help it actually win the fight.
That fits with the broader rezatapopt story. Preclinical work in other Y220C-mutant cancers showed the drug could restore tumor-suppressor function, and clinical development in solid tumors has already offered proof that the target is real and druggable [5,6]. The AML paper adds a reality check: same mutation, different neighborhood. Leukemia has its own rules, and they are rude.
If these findings hold up in patients, the real-world payoff could be big. Instead of treating all TP53-mutant AML as one gloomy bucket, doctors may be able to go after a specific mutant shape with a matching drug and rational combinations. That is precision medicine in the non-buzzword sense. Not magic. Not a miracle. Just a smarter way to stop guessing.
References
-
Carter BZ, Mak PY, Ayoub E, et al. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. Blood. 2025;146(21):2574-2588. DOI | PMCID
-
Zhao Y, Chen W, Yu J, et al. TP53 in MDS and AML: Biological and clinical advances. Cancer Letters. 2024;588:216767. DOI | PubMed
-
Russo D, Malagola M, Iurlo A, et al. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer Journal. 2024;14:202. DOI | PMCID
-
Sahasrabudhe KD, Mims AS. Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3. Hematology Am Soc Hematol Educ Program. 2022;2022(1):15-22. DOI | PMCID
-
Puzio-Kuter AM, Xu L, McBrayer MK, et al. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discovery. 2025;15(6):1159-1179. DOI | PMCID
-
Ma Z, Shen Q, Zhou J. Rezatapopt (PC14586): A First-in-Class Small Molecule p53 Y220C Mutant Protein Stabilizer in Clinical Trials. Journal of Medicinal Chemistry. 2025;68(7):6847-6849. DOI
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.